Re-focusing the ethical discourse on personalized medicine: A qualitative interview study with stakeholders in the German healthcare system

BMC Medical Ethics

Volumn 14, Issue 1, 2013, Pages

  Schleidgen, Sebastian ^a   Marckmann, Georg ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ECONOMICS; ETHICS; GERMANY; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; INSURANCE; MEDICAL RESEARCH; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PERSONNEL; PRIMARY PREVENTION; QUALITATIVE RESEARCH; STANDARD; VERBAL COMMUNICATION;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DELIVERY OF HEALTH CARE; DRUG INDUSTRY; GERMANY; HUMANS; INDIVIDUALIZED MEDICINE; INSURANCE CARRIERS; INSURANCE, HEALTH; MOLECULAR TARGETED THERAPY; NARRATION; PRIMARY PREVENTION; QUALITATIVE RESEARCH; RESEARCH PERSONNEL;

EID: 84878008751     PISSN: None     EISSN: 14726939     Source Type: Journal    
DOI: 10.1186/1472-6939-14-20     Document Type: Article

References (26)

1. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? Fierz W, Med Sci Monit 2004 10 111 123
2. Foundations, promises and uncertainties of personalized medicine. Bottinger EP, Mt Sinai J Med 2007 74 15 21 10.1002/msj.20005 17516562
3. Hüsing B, Hartig J, Bührlen B, Individualisierte Medizin und Gesundheitssystem Berlin: TAB beim Bundestag 2008
4. Delivering on the promise of personalized healthcare. March R, Pers Med 2010 7 327 337 10.2217/pme.10.17
5. Nuffield Council on Bioethics, Pharmacogenetics: ethical issues London: Nuffield Council on Bioethics 2003
6. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Smart A, Martin P, Parker M, Bioethics 2004 18 322 343 10.1111/j.1467-8519.2004.00400.x 15449405
7. You are born with your genes: justice and protection against discrimination in the use of genetic information. Francis PF, Mt Sinai J Med 2010 77 188 196 10.1002/msj.20170 20309923
8. Regulatory and ethical challenges of personalized medicine. Torr-Brown SR, Pers Med 2010 7 465 468 10.2217/pme.10.49
9. From patients to partners: participant-centric initiatives in biomedical research. Kaye J, Curren L, Anderson N, Nat Rev Genet 2012 13 371 377 10.1038/nrg3218 22473380
10. What German experts expect from individualized medicine: problems of uncertainty and future complication in physician-patient interaction. Heßling A, Schicktanz S, Clinical Ethics 2012 7 86 93 10.1258/ce.2012.12- 001
11. In Deutschland zugelassene Arzneimittel für die personalisierte Medizin http://www.vfa.de/personalisiert (accessed 23 May 2013)
12. Given LM, The Sage Encyclopedia of Qualitative Research Methods Vol. 2 Thousand Oaks: Sage Publications 2008
13. Mayring P, Qualitative Inhaltsanalyse Weinheim, Beltz: Grundlagen und Techniken 2003
14. Roche Position on Personalised Healthcare http://www.roche.com/position- personalised-healthcare.pdf (accessed 23 May 2013)
15. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Slamon DJ, Clark GM, Wong SG, Science 1987 235 177 182 10.1126/science.3798106 3798106
16. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, Leyland-Jones B, Shak S, New Engl J Med 2001 344 783 792 10.1056/NEJM200103153441101 11248153
17. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, New Engl J Med 2005 353 1659 1672 10.1056/NEJMoa052306 16236737
18. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. Romond EH, Perez EA, Bryant J, New Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122 16236738
19. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for breast cancer. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, New Engl J Med 2006 354 809 820 10.1056/NEJMoa053028 16495393
20. Ethical considerations in clinical pharmacogenomics research. Issa AM, Trends Pharmacol Sci 2000 21 247 249 10.1016/S0165-6147(00)01493-0 10871892
21. Pharmacogenetics: legal, ethical and regulatory considerations. March R, Cheeseman K, Doherty M, Pharmacogenomics 2001 2 317 327 10.1517/14622416.2.4.317 11722282
22. Pharmacogenomics: out of the lab and into the community. Nebert DW, Bingham E, Trends Biotechnol 2001 19 519 523 10.1016/S0167-7799(01)01805-4 11711196
23. Pharmakogenetische Tests in der zukünftigen medizinischen Versorgung: Implikationen für Patienten und Ärzte. Rogausch A, Brockmöller J, Himmel W, Gesundheitswesen 2005 67 257 263 10.1055/s-2004-813918 15856385
24. Six-year follow-up of patients receiving Imatinib for the first-line treatment of chronic myeloid leukemia. Hochhaus A, O'Brien SG, Guilhot F, Leukemia 2009 23 1054 1061 10.1038/leu.2009.38 19282833
25. Addition of Cetuximab to Oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Maughan TS, Adams RA, Smith CG, Lancet 2011 377 2103 2114 10.1016/S0140-6736(11)60613-2 21641636
26. The precautionary principle and medical decision making. Resnik DB, J Med Philos 2004 29 281 299 10.1080/03605310490500509 15512973